Unlock the future of cell and gene therapy manufacturing at the 2nd Raw Materials for Cell and Gene Therapy Summit. This is your exclusive opportunity to hear directly from regulatory and standards leaders such as Andrew Sarafanov (FDA) and Rebecca Potts (USP), as they share the latest thinking on BLA review expectations, raw material characterization, and the evolving global standards landscape. With the cell and gene therapy industry facing increasing complexity and supply chain uncertainty, top innovators from Vertex, Genentech, and Bristol Myers Squibb will reveal how they're reengineering supplier strategies, through dual sourcing, co-development, and rigorous vendor qualification.